IMMUNE · Injectable
Bronchogen.
Lung/bronchial bioregulator — Khavinson cytomedicine
How it works
Class & mechanism.
In short
Bronchogen is a 4-amino-acid tetrapeptide developed by Professor Vladimir Khavinson as part of a Russian "organotropic" bioregulator system targeting specific organs — in this case, lung and bronchial tissue. It is proposed to act through gene-switching signals that modulate bronchial epithelial cell function, though no human pharmacokinetic studies or Western clinical trials exist to confirm this mechanism or its effects. It has no regulatory approval outside Russia and is used in Western contexts strictly as a research chemical.
Class
Tetrapeptide Bioregulator (Khavinson cytomedicine)
Mechanism
Bronchogen (Ala-Glu-Asp-Leu) is a tetrapeptide developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Classified as a lung/bronchial tissue bioregulator, it is proposed to normalize bronchial epithelial cell function through gene-switching signalling — binding to histone proteins and modulating gene expression in target tissue. Extremely small molecular weight (~430 Da) may allow partial oral bioavailability, though no formal human PK studies exist. Used clinically in Russia for respiratory support; not approved in Western markets.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
Bronchogen is one of a family of "organotropic" tetrapeptides developed in Russia — each just 4 amino acids long, each targeting a specific organ. At ~430 daltons, it's small enough to potentially survive digestion, making it one of the rare peptides that may work orally.
Preclinical Data
No human PK studies available.
Russian cytomedicine — no independent PK data
Class
Tetrapeptide lung bioregulator (Khavinson cytomedicine)
Route
SC / Oral
Mol. Weight
430.5 Da
What we don't know
No human PK studies exist. As a small tetrapeptide (~430 Da), absorption is expected to be rapid. Oral bioavailability may be partial given small size allowing some GI survival. All PK parameters are extrapolated from size and class characteristics.
Why this dosing protocol
Khavinson protocol: 5-10mg SC daily for 10-30 days per course, repeated 2-3× per year for respiratory health maintenance. Oral capsule formulations (10-20mg) are also sold as dietary supplements in Russia. The tissue-specific bioregulator concept posits that effects persist for months after the short course concludes.
Empirical protocol: 5-10mg SC daily × 10-30 days
Safety notes
- Russian-only data
- No Western peer replication
Sources
Pharmacokinetic data shown for educational context. All parameters are inferred or empirically derived — no formal human PK studies exist for this compound. Individual response varies. Not a substitute for clinical dosing guidance.
Benefits
What it does.
Respiratory tissue support — proposed to normalize bronchial epithelial cell function in ageing and chronic respiratory conditions, based on Khavinson group hypotheses rather than confirmed human outcomes
Lung-specific bioregulation — classified within the Khavinson organotropic peptide system, which proposes tissue-specific targeting of pulmonary repair pathways
Anti-inflammatory signalling — may help reduce bronchial inflammation through tissue-specific regulatory mechanisms, per the proposed gene-switching model
Age-related respiratory decline — used in Russian gerontology protocols intended to support lung function in elderly patients, though independent verification is limited
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
Bronchogen is a research chemical. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. Bronchogen is not FDA-approved for respiratory support, bronchial tissue repair, or any other use, and has no independent Western clinical or pharmacokinetic data — all available evidence comes from Russian laboratory and gerontology sources. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
Khavinson group publications in Bulletin of Experimental Biology and Medicine report lung tissue effects and proposed epigenetic gene-switching mechanism for tetrapeptide bioregulators
SOURCE · Khavinson VKh et al., Bulletin of Experimental Biology and Medicine (multiple years); St. Petersburg Institute of Bioregulation
Protocol
How to use it.
Dosing
5–10 mg per subcutaneous injection, 1–2× per day for 10–30 day courses. Oral formulations available at 10–20 mg per capsule.
Cycle
10–30 day course, repeated 2–3× per year. Standard Khavinson protocol: 10–20 day pulse with 4–6 month rest between courses.
Contraindications
When to skip it.
No human PK studies exist. No Western regulatory approval. All dosing is empirical based on Russian laboratory protocols. Use under physician supervision only. Not evaluated by FDA.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| No specific FDA action | 🟢 Stable | Gray zone — no specific enforcement | No pending dates |
Lung/bronchial bioregulator — Khavinson cytomedicine class. Not on any FDA Category 1/2/3 lists. No pending PCAC review.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for Bronchogen, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Bronchogen pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $112–$168 USD